News & Updates
Filter by Specialty:
Recurrence scores from 21-gene assay help inform benefits of adjuvant anthracyclines in EBC
The recurrence score derived from a 21-gene expression assay may indicate which patients with early-stage HR+ breast cancer can maintain freedom from distant recurrence for longer with the inclusion of an anthracycline in adjuvant chemotherapy, suggests a post hoc analysis of the TAILORx trial presented at SABCS 2024
Recurrence scores from 21-gene assay help inform benefits of adjuvant anthracyclines in EBC
26 Jan 2025
Toripalimab plus chemo a good 1st-line CHOICE for advanced NSCLC
The prespecified final analysis of the phase III CHOICE-01 trial of toripalimab in combination with chemotherapy shows significant improvement in overall survival (OS) in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) without EGFR/ALK driver mutations.
Toripalimab plus chemo a good 1st-line CHOICE for advanced NSCLC
22 Jan 2025
Could intermediate use of H1-antihistamines alongside ICIs extend OS in lung cancer?
A retrospective territory-wide cohort study by the Chinese University of Hong Kong (CUHK) reports an association between intermediate use of H1-antihistamines and longer overall survival (OS) in patients with lung cancer treated with immune checkpoint inhibitors (ICIs).
Could intermediate use of H1-antihistamines alongside ICIs extend OS in lung cancer?
22 Jan 2025
Add-on ibrutinib ENRICHes rituximab treatment effect for previously untreated MCL
In the phase II/III ENRICH trial, first-line (1L) ibrutinib with rituximab (IR) demonstrates superiority over rituximab plus chemotherapy (R-chemo; either R-CHOP* or bendamustine**-R) in older patients with previously untreated mantle cell lymphoma (MCL).
